282 related articles for article (PubMed ID: 21962244)
1. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
Jiao Y; Ou W; Meng F; Zhou H; Wang A
Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Ou WB; Hubert C; Corson JM; Bueno R; Flynn DL; Sugarbaker DJ; Fletcher JA
Neoplasia; 2011 Jan; 13(1):12-22. PubMed ID: 21245936
[TBL] [Abstract][Full Text] [Related]
3. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
4. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
Wang S; Pashtan I; Tsutsumi S; Xu W; Neckers L
Cell Cycle; 2009 Jul; 8(13):2050-6. PubMed ID: 19502802
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
[TBL] [Abstract][Full Text] [Related]
6. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
7. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
8. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
9. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
10. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K
Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813
[TBL] [Abstract][Full Text] [Related]
11. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
Kim NY; Lee HY; Lee C
Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
Calero R; Morchon E; Martinez-Argudo I; Serrano R
Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
[TBL] [Abstract][Full Text] [Related]
13. AXL Downstream Targeting Unravels Synergistic Drug Combinations in Ovarian Carcinoma Cells.
Alampi DM; Ciusani E; Carenini N; Corna E; Gatti L; Corno C
Anticancer Res; 2019 Jul; 39(7):3803-3808. PubMed ID: 31262907
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
Suh YA; Jo SY; Lee HY; Lee C
Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
[TBL] [Abstract][Full Text] [Related]
15. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Mahadevan D; Theiss N; Morales C; Stejskal AE; Cooke LS; Zhu M; Kurtzman D; Swart R; Ong E; Qi W
Oncotarget; 2015 Feb; 6(4):1954-66. PubMed ID: 25557174
[TBL] [Abstract][Full Text] [Related]
16. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.
Citri A; Kochupurakkal BS; Yarden Y
Cell Cycle; 2004 Jan; 3(1):51-60. PubMed ID: 14657666
[TBL] [Abstract][Full Text] [Related]
17. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
[TBL] [Abstract][Full Text] [Related]
18. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
19. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
20. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]